TY  - JOUR
TI  - The role of diffusion-weighted imaging on 3 tesla magnetic resonance in the clinical
staging and pathological grading of clear cell renal carcinoma
AB  - Aim: To evaluate the contribution of the apparent diffusion coefficient (ADC) to distinguish between the four
clinical stages and pathological grading in patients with clear cell renal cell carcinoma (RCC) on 3T MRI.
Methods: MRI of 93 patients with histopathological diagnosis of clear cell RCC were evaluated
retrospectively. Clinical stage was evaluated according to American Joint Committee on Cancer and
histopathological examination was evaluated according to the Fuhrman grading system. ADC values were
compared for each clinical stage and pathological grade.
Results: Clinical stages were I in 51 patients (54.8%), II in 14 patients (15%), III in 15 patients (16.1%), and
IV in 13 patients (13.9%). The Fuhrman grade of the patients were I in 8 (8.6%) patients, II in 55 (59.1%)
patients, III in 23 (24.7%) patients and IV in 7 (7.5%) patients. Clinical stage I and Fuhrman grade I had
significantly higher ADC values than all groups (p<0.001). The sensitivity was 81% and the specificity was
80.4% when the optimum cut-off value of ADC was taken as 1.41×10−3 mm2/s to differentiate between clinical
stage I and other stages (II, III, and IV) (AUC:0.910; 95CI:0.855-0.964; p<0.001). The optimum cutoff value
of ADC was taken as 1.67×10−3 mm2/s to differentiate between Fuhrman grade I and other grades (II, III and
IV), the sensitivity was 88.2% and the specificity was 100% (AUC: 0.927; 95CI: 0.872- 0.983; p<0.001).
Conclusions: In patients with renal mass suggestive of clear cell RCC in imaging studies; The possibility of
lymph node or distant metastatic lesion should be considered in patients with an ADC of the primary tumor
site less than 1.41×10−3 mm2/s, and the presence of distant metastasis in patients with an ADC less than
1.22×10−3 mm2/s.
AU  - EREN, Huseyin
AU  - erok, berrin
AU  - GÜNDOĞDU, HASAN
AU  - Bedir, Recep
DO  - 10.30714/j-ebr.2022173857
PY  - 2022
JO  - Experimental Biomedical Research
VL  - 5
IS  - 1
SN  - 2618-6454
SP  - 125
EP  - 134
DB  - TRDizin
UR  - http://search/yayin/detay/523526
ER  -